Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Dunner

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
The Journal of Clinical Psychiatry|August 10, 2007
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT StudyJames H Kocsis, Michael E Thase, Madhukar H Trivedi, et al.
Brain Stimulation|November 6, 2012
Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effectsScott T Aaronson, Linda L Carpenter, Charles R Conway, et al.
Biological Psychiatry|September 11, 2007
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phasesMartin B Keller, Madhukar H Trivedi, Michael E Thase, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 4, 2004
Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatientsA John Rush, Madhukar H Trivedi, Thomas J Carmody, et al.
The Journal of Clinical Psychiatry|September 15, 2007
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phasesMartin B Keller, Madhukar H Trivedi, Michael E Thase, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|May 7, 2019
The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysisLynn Boschloo, Ella Bekhuis, Erica S Weitz, et al.
Brain Stimulation|April 4, 2024
Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial reportCharles R Conway, Scott T Aaronson, Harold A Sackeim, et al.
Brain Stimulation|December 19, 2024
Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-controlled trialA John Rush, Charles R Conway, Scott T Aaronson, et al.
Brain Stimulation|December 20, 2024
Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trialCharles R Conway, Scott T Aaronson, Harold A Sackeim, et al.
The International Journal of Neuropsychopharmacology|January 13, 2026
Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial reportCharles R Conway, Augustus John Rush, Scott T Aaronson, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
The Journal of Clinical Psychiatry|August 10, 2007
Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT StudyJames H Kocsis, Michael E Thase, Madhukar H Trivedi, et al.
Brain Stimulation|November 6, 2012
Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effectsScott T Aaronson, Linda L Carpenter, Charles R Conway, et al.
Biological Psychiatry|September 11, 2007
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phasesMartin B Keller, Madhukar H Trivedi, Michael E Thase, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 4, 2004
Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatientsA John Rush, Madhukar H Trivedi, Thomas J Carmody, et al.
The Journal of Clinical Psychiatry|September 15, 2007
The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phasesMartin B Keller, Madhukar H Trivedi, Michael E Thase, et al.
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|May 7, 2019
The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysisLynn Boschloo, Ella Bekhuis, Erica S Weitz, et al.
Brain Stimulation|April 4, 2024
Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial reportCharles R Conway, Scott T Aaronson, Harold A Sackeim, et al.
Brain Stimulation|December 19, 2024
Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-controlled trialA John Rush, Charles R Conway, Scott T Aaronson, et al.
Brain Stimulation|December 20, 2024
Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trialCharles R Conway, Scott T Aaronson, Harold A Sackeim, et al.
The International Journal of Neuropsychopharmacology|January 13, 2026
Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial reportCharles R Conway, Augustus John Rush, Scott T Aaronson, et al.
Pageof 11